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ABSTRACT
There is an urgent public health need for early and reliable detection of methicillin-resistant
Staphylococcus aureus (MRSA) infection and carriage to direct antibiotic therapy, to inform patient
isolation and decontamination procedures, and to more effectively control cross-infection. Limited
advances have been made in culture-based tests, while considerable promise is offered by a new
generation of molecular assays based on real-time PCR. Several commercially available PCR tests can
rapidly detect MRSA from nasal swabs with high sensitivity and speciﬁcity (both 90–100%),
although technical issues remain to be resolved and comparative data are lacking. Crucially,
evidence must be provided for the clinical efﬁcacy, effectiveness and cost–beneﬁt of implementing
these technologies. Furthermore, adaptations in healthcare systems and professional behaviour will
be required if full advantage is to be taken of any truly rapid, point-of-care tests that become
available.
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INTRODUCTION
Methicillin-resistant Staphylococcus aureus
(MRSA) strains have become endemic pathogens
in many healthcare facilities and are also spread-
ing in the community. MRSA infection is causing
increased public concern worldwide, as it carries
a signiﬁcant risk of morbidity and mortality, and
has been linked to substantial excess healthcare
costs [1].
The increased risk of prolonged hospital stay
and fatal outcome from bloodstream or surgical
infection with MRSA, as compared with no
infection or infection with methicillin-susceptible
S. aureus (MSSA), has been well-documented [1].
Possible explanations for these adverse prognostic
features of severe MRSA infection include differ-
ences in strain virulence, higher likelihood of
delayed appropriate antimicrobial therapy, and
the inferior activity and clinical efﬁcacy of glyco-
peptides as compared with b-lactams for the
therapy of severe staphylococcal infections. This
last aspect is particularly the case for strains with
decreased glycopeptide susceptibility, or glyco-
peptide-intermediate S. aureus. Therefore, there is
a medical need for rapid diagnosis of MRSA
infection to guide early appropriate treatment
with active drugs.
In addition, much interest has arisen concerning
the key role of MRSA carrier screening for the
efﬁcient control of MRSA within healthcare facil-
ities. Active surveillance cultures for MRSA are
now part of clinical practice recommendations in
both Europe and the USA [2–4]. Indeed, studies
have indicated that up to 70% of the patient
reservoir for MRSA among hospitalised patients
can only be detected by active sampling and
selective cultures of mucocutaneous colonisation
sites, including the nares, throat, skin, wounds,
rectum and insertion sites for invasive devices.
MRSA colonisation places the individual patient at
increased risk of healthcare-associated infection
and constitutes a reservoir for transmission to
other hospitalised patients. There is an urgent
public health need for early and reliable detection
of carriers of MRSA among patients admitted to
healthcare facilities, to inform patient isolation and
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decontamination procedures, and thereby more
effectively control cross-infection [5].
CULTURE-BASED MRSA DETECTION
Currently, culture-based methods are still the
mainstay for MRSA detection. Standard identi-
ﬁcation and susceptibility testing methods
require 24 h of incubation, starting from a pure
culture on agar medium for reliable MRSA
identiﬁcation. MRSA identiﬁcation is achieved
in <12 h with >98% sensitivity and >99%
speciﬁcity after isolation in pure culture by
automated bacterial identiﬁcation and antimi-
crobial susceptibility testing systems such as the
Phoenix System (Becton-Dickinson, Sparks, MD,
USA) and Vitek II system (bioMe´rieux, Marcy-
l’Etoile, France) [5].
The fastest phenotypic test for MRSA is based
on immunodetection of S. aureus surface anti-
gens and low-afﬁnity penicillin-binding protein
2a with monoclonal antibody-coated latex
particles (MRSA-Screen; Denka Seiken, Tokyo,
Japan). This technique provides results in
15 min with accuracy similar to that of a pure
culture. The Crystal MRSA assay (Becton-
Dickinson) affords reliable oxacillin resistance
testing by ﬂuorescence quenching as a growth
indicator after 5 h of incubation [5].
Detection of MRSA in surveillance cultures of
mucocutaneous swab specimens is typically
performed by using selective and differential
agar media, sometimes enhanced with enrich-
ment broth culture, which is incubated over-
night before being plated on selective agar [3,5].
Traditional media contain an indicator system
to presumptively identify S. aureus, such as
mannitol and a pH indicator such as phenol
red combined with inhibitory agents such as
sodium chloride at high concentrations, or
antimicrobial agents. These media usually
require 48–72 h before a presumptive identiﬁca-
tion can be made. This is followed by conﬁr-
mation on isolated colonies by additional tests
that require up to 24 h [5].
New selective agar media supplemented with
cefoxitin and chromogenic enzyme substrates
have shown improved performance, with some
media allowing MRSA identiﬁcation with >80%
sensitivity and 99% speciﬁcity after 18–24 h
and with 95–100% sensitivity and >90% specif-
icity after 42–48 h [5,6]. Further comparative
evaluation of chromogenic MRSA screening
media is awaited [5].
MOLECULAR ASSAYS
Recently developed molecular assays for MRSA
detection are undergoing clinical and economic
evaluation. The ﬁrst-generation tests were based
on multiplex PCR detection of two targets: the
resistance determinant mecA, and S. aureus-speci-
ﬁc genes (nuc, femA, coa). Although these assays
are sensitive enough for rapid (<4 h) detection in
broth cultures from blood or swab specimens,
they suffer from limited sensitivity and poor
speciﬁcity in specimens with mixed ﬂora contain-
ing methicillin-resistant coagulase-negative sta-
phylococci and MSSA.
Current real-time PCR assays are more sensi-
tive, with an analytical detection level in the
range of ten genome copies. Several real-time
PCR and other DNA ampliﬁcation methods have
shown good sensitivity when used on enrich-
ment broth following overnight incubation, but
these assays do not provide rapid results.
A commercial real-time PCR test, the IDI-MRSA
(GeneOhm Sciences, Montreal, Que´bec, Canada),
is designed to target MRSA-speciﬁc DNA ele-
ments that bridge the SCCmec chromosomal
junction (orfX) [7]. This design prevents false-
positive signals from mixed ﬂora specimens
containing MSSA and methicillin-resistant coagu-
lase-negative staphylococci. Such co-colonisation
is found in approximately 3–5% of nasal swab
samples from hospitalised patients. However,
this PCR assay is potentially affected by mecA
deletion from SCCmec elements (giving a false-
positive signal from MSSA strains) and by
divergent sequence variants in SCCmec (giving
a false-negative signal from MRSA strains).
Validation studies on international S. aureus
strain collections and clinical samples indicate
that these atypical strains are rare [7].
Prospective clinical evaluations of the IDI-
MRSA assay have shown that MRSA can be
detected in 2 h with high sensitivity and specif-
icity from nasal swabs and with a somewhat
lower performance from skin swabs (Table 1)
[7–9]. Real-time multiplex PCR on the LightCycler
system (Roche Applied Sciences, Indianapolis, IN,
USA) has also shown promising performance in
testing nasal swabs from neonates and adult
patients [10]. Another real-time PCR assay with
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good performance results in one centre used an
immuno-magnetic separation step for selective
MRSA concentration prior to DNA extraction and
ampliﬁcation [11,12] (Table 1).
A number of technical issues related to the
performance of real-time PCR for MRSA screen-
ing remains to be studied, including the accu-
racy on specimens other than nasal swabs, the
number of swab ⁄ sites per patient for optimal
sampling, and the comparative evaluation of
existing assays. In addition, the goal of screen-
ing assays should not be restricted to rapid
MRSA detection, but should also include detec-
tion of resistance to mupirocin. Mupirocin is
used for decolonisation therapy and ultimately
also genotyping, and detection of resistance to
this agent could be achieved by sequence
analysis of the X region of the spa gene. Without
demonstration of these capacities, it is likely
that implementation of PCR screening would
still need to be backed up by conventional
culture systems.
BENEFIT ANALYSIS FOR MRSA
ASSAYS
The implementation of routine high-volume sur-
veillance testing using these molecular assays is
associated with signiﬁcant costs. Accordingly,
their added medical value and cost-effectiveness
for facilities ﬁghting healthcare-associated MRSA
infection must be demonstrated (Table 2).
Published clinical studies that have evaluated
the clinical utility of rapid identiﬁcation of MRSA
for patient management are few in number and
suffer from a number of methodological limita-
tions. No deﬁnite evidence of improved patient
outcomes resulting from such diagnostic tests is
yet available, although some prospective cohort
studies have indicated their potential for increas-
ing the proportion of infected patients receiving
appropriate treatment [13]. Likewise, the studies
that document the impact of rapid MRSA carrier
screening on outbreak management and control
of MRSA transmission within hospitals are sub-
ject to some degree of bias, such as an uncon-
trolled before–after design [12]. Evidence from
such intervention studies and from mathematical
modelling suggests that enhanced rapidity and
accuracy of molecular MRSA screening embed-
ded in the ‘search-and-destroy’ policy is highly
cost-beneﬁcial at the hospital level in both
endemic and low-prevalence settings [14]. Well-
designed multicentre intervention trials are
underway which should clarify the medical and
ﬁnancial added value of these strategies in
diverse healthcare systems.
CONCLUSION
Several obstacles are limiting the routine imple-
mentation and extensive use of molecular
technologies for the identiﬁcation of MRSA in
clinical specimens. First, robust evidence must be
Table 1. Diagnostic performance of real-time PCR assays for detection of methicillin-resistant Staphylococcus aureus
directly from screening specimens
Method Target Instrument Specimens Sensitivity (%) Speciﬁcity (%) TAT (h)
TaqMan [11] mecA ⁄ femA ABI Prism 7700 Nasal, inguinal swabs 100 64 6
SYBR Green [10] mecA ⁄ femA LightCycler Nasal swabs 98 99 2
IDI-MRSA [7–9] SCCmec–OrfX SmartCycler Nasal swabs
Skin swabs
89–100
82
93–97
92
2
TAT, turn-around time.
Table 2. Potential beneﬁts of rapid methicillin-resistant
Staphylococcus aureus (MRSA) identiﬁcation in clinical and
screening specimens
A. Clinical specimens: patient care outcomes
Early appropriate treatment
Clinical and bacteriological cure
Reduced empirical use of glycopeptides
Cost savings due to shorter patient stay
B. Screening specimens: infection control outcomes
Early MRSA patient isolation ⁄ cohorting
Increase in MRSA carrier decolonisation rate
Decrease in nosocomial MRSA transmission rate
Decrease in MRSA morbidity and mortality
Cost saving due to shorter patient stay
Avoidance of unnecessary isolation of at-risk patients
Cost saving due to fewer preventive isolation days
Lower medical liability costs
Decreased use of glycopeptides
Lower risk of emergence of glycopeptide-resistant
enterococci and staphylococci
Struelens Rapid identiﬁcation of MRSA 25
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12 (suppl 9), 23–26
provided for the clinical efﬁcacy, effectiveness
and cost–beneﬁt of their implementation in dif-
ferent epidemiological settings. Second, current
technologies remain labour-intensive and
dependent on skilled personnel, thereby making
24-h ⁄ 7 days a week routine testing a major
logistic challenge for any laboratory. Thus, there
remains a technological gap for a self-operated,
point-of-care or core-laboratory-based assay for
round-the-clock routine MRSA identiﬁcation in
clinical and screening specimens.
Finally, making optimal use of such rapid
diagnostic tools will require changes in healthcare
systems and the modiﬁcation of professional
behaviour towards patient care and infection
control. In other words, taking advantage of
exciting technical opportunities for microbiology
will require multidisciplinary technology assess-
ment and system-wide practice change. There is
no doubt that the societal and health costs of
antibiotic-resistant S. aureus infections warrant a
concerted effort to solve this problem.
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